Citations 1
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension
Pittock, Sean J. , Palace, Jacqueline , Kim, Ho Jin , Nakashima, Ichiro , Levy, Michael , Shang, Shulian, Yountz, Marcus, Miller, Larisa , Armstrong, Róisín, Wingerchuk, Dean M. , Group, the PREVENT Study, Palace, Jacqueline , Kim, Ho Jin , Oreja-Guevara, Celia , Nakashima, Ichiro , Levy, Michael , Pittock, S J , Palace, Jacqueline , Fujihara, Kazuo , Berthele, Achim , Oreja‐Guevara, Celia , Group, the PREVENT Study
Multiple Sclerosis Journal | September 9, 2021 | Volume: 28 | Issue: 3 | Pages: 480-486
During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks–5.2 years). At 192 weeks (~4 years), 96% of these patients were free from adjudicated relapses (Kaplan–Meier analysis; 95% confidence interval, 75.7–99.4). During PREVENT, 95% (20/21) of patients receiving eculizumab monotherapy had no disability worsening. Eculizumab monotherapy provides effective long-term relapse prevention, relieving the chronic immunosuppression burden in patients with AQP4-IgG + NMOSD. ClinicalTrials.gov; PREVENT: NCT01892345; open-label extension: NCT02003144.